Galapagos

Galapagos NV has appointed Aaron Cox as Chief Financial Officer effective July 7, 2025, bringing over two decades of biotechnology and M&A expertise to the Belgian biotech company.

• e-therapeutics has presented new preclinical data demonstrating ETX-312, their GalOmic siRNA candidate, significantly improves NAFLD Activity Score in MASH mouse models both as monotherapy and in combination with other agents. • The experimental treatment showed comparable fibrosis progression reduction to GLP-1/GIP receptor agonists and FGF-21 analogues, with statistically significant reductions in hepatic collagen staining and circulating biomarkers. • ETX-312, currently in IND-enabling studies, is being developed with potential for quarterly subcutaneous dosing, with regulatory submission planned by the end of 2025.

• AbbVie has partnered with Galapagos NV in a global alliance worth up to $406 million to discover and develop combination therapies targeting key mutations in cystic fibrosis patients. • The collaboration aims to develop oral drugs addressing F508del and G551D mutations in the CFTR protein, with plans to initiate Phase 1 clinical trials by the end of 2014. • This partnership joins other significant industry efforts to combat cystic fibrosis, including Pfizer's expanded six-year research program with the Cystic Fibrosis Foundation worth up to $58 million.

• Galapagos NV initiates HESPERIA study to monitor long-term safety and efficacy of their CAR-T therapies across multiple hematologic malignancies over a 15-year period. • The company's lead candidate GLPG5101, targeting CD19, demonstrates potential 7-day manufacturing time and is being evaluated for various B-cell malignancies including DLBCL and follicular lymphoma. • HESPERIA study aims to enroll 546 patients across European sites, tracking critical endpoints including adverse events, CAR transgene levels, and overall survival rates.

Catalent and Galapagos NV have formed a strategic collaboration to support decentralized manufacturing of GLPG5101, an investigational CAR-T therapy for relapsed/refractory non-Hodgkin lymphoma.

• Galapagos NV secured FDA IND clearance for GLPG5101, a CAR-T therapy, enabling U.S. patient recruitment for Phase II ATALANTA study in non-Hodgkin lymphoma. • The company is progressing over 15 programs, planning at least four IND-enabling studies in 2025, focusing on oncology and immunology. • Strategic collaborations with Blood Centers of America and Adaptimmune are expanding Galapagos' cell therapy manufacturing network and capabilities. • Galapagos maintains a strong cash position of EUR 3.3 billion, supporting its R&D efforts and business development opportunities in oncology and immunology.